Concepts and challenges in the use of mesenchymal stem cells as a treatment for cartilage damage in the horse.

The research article investigates the potential of using mesenchymal stem cells (MSCs) to regenerate damaged cartilage in horses and prevent osteoarthritis, a common joint disease. The study assesses the usage challenges along with an analysis of two different types of MSCs and their associated responses when injected into a horse’s joint.

Understanding Osteoarthritis and Stem Cell Therapy

• The researchers are studying the application of regenerative therapies for joint diseases such as osteoarthritis (OA) in horses, which is similar to OA in humans.
• OA is characterized by progressive damage to joint cartilage, eventually leading to reduced functionality of the affected joint.
• Regenerative therapies operate on the assumption that MSCs can halt the advance of cartilage damage and potentially help regenerate the diseased tissue, thereby preventing OA.
• The challenges in using this treatment technique involve considerations concerning the type of MSCs in use (allogenic or autologous), the timing and dosage of the MSCs and their source.

Study 1: Comparing Different Sources of MSCs

• The first study compared bone marrow-derived MSCs (BMMSCs) and Synovial fluid-derived MSCs (SFMSCs) from the same donors in vitro.
• Results indicated that both cell types had similar rates of proliferation and expression of CD29, CD44, and CD90 — important markers that indicate the cell’s ability to differentiate and proliferate.
• However, the chondrogenesis (the process by which cartilage is formed) was significantly different in both MSCs, with a small percentage of SFMSCs exhibiting major histocompatibility complex II (MHC II) features unlike the BMMSCs.

Study 2: Evaluating Responses to Injection of MSCs into Joints

• In the second study, both autologous and allogenic SFMSCs were injected into the tarsocrural joint of horses.
• Results showed an increase in total protein and the count of nucleated cells upon injection of both cell types, indicating an initial bodily response to the introduction of the MSCs.
• This indicates a need for further investigation of the acute or chronic bodily responses to allogenic or autologous MSC injections.

Conclusion and Next Steps

• The research provides valuable insights into the potential of using MSCs in treatment of cartilage damage, though it also suggests that optimal use of MSCs would need to navigate various challenges.
• Future studies are required to better understand the in vivo acute or chronic responses to MSCs and how those factors might influence treatment effectiveness.